In an era of genetic testing, advanced imaging and multi-cancer blood tests, the single most cost-effective tool for identifying who needs closer surveillance is also the oldest one: a carefully taken family history. It costs nothing. It takes 20 minutes. And it frequently changes what should be done: in one large US primary-care study, a structured family-history assessment flagged about three quarters of participants for at least one risk-based recommendation, such as earlier screening or genetic counselling.

Why three generations matter

A useful family history covers three generations: parents, siblings, children and all four grandparents. For each relative, the critical information is: which diseases did they develop, and at what age? The age of onset is often more important than the diagnosis itself.

A father who had a heart attack at age 72 suggests age-related cardiovascular disease — concerning but expected. A father who had a heart attack at age 48 suggests a heritable lipid disorder, possibly familial hypercholesterolemia, and completely changes the risk assessment for every first-degree relative.

Similarly, colorectal cancer at 75 is common. Colorectal cancer at 42 raises the question of Lynch syndrome — a hereditary condition that affects 1 in 279 people and dramatically increases the risk of colon, endometrial, ovarian and other cancers. Confirmed carriers are advised to start colonoscopy at 20–25, rather than at the usual screening age (45 in the US, 50 in Germany); relatives can be tested to find out whether they carry the family variant.

What family history changes in practice

  • Cardiovascular disease in a first-degree relative before 55 (men) or 65 (women): Reclassifies a person to higher cardiovascular risk. A good reason to measure ApoB and Lp(a). May indicate familial hypercholesterolemia — which affects 1 in 250 people and is dramatically undertreated.
  • Colorectal cancer before 50 in a first-degree relative: US guidelines advise starting colonoscopy 10 years before the relative's age at diagnosis (or at 40, whichever is earlier); details differ by country. Consider genetic testing for Lynch syndrome.
  • Breast/ovarian cancer before 50, or multiple cases: Consider BRCA testing. If positive, screening and risk-reduction strategies change fundamentally.
  • Type 2 diabetes in parents: A family history of diabetes roughly doubles to triples the risk (about 2.6-fold in a large European study); two affected parents raise it about fivefold. Strengthens the case for HOMA-IR monitoring and early lifestyle intervention.
  • Multiple cancers in the family before age 50: Raises suspicion of a hereditary cancer syndrome and is a reason for genetic counselling. If a syndrome such as Li-Fraumeni (TP53) is confirmed, guidelines recommend annual whole-body MRI — one of the few clinical scenarios in which it is considered justified.

The problem

Most routine check-ups do not include a proper family history. The physician asks "any family history of heart disease or cancer?" — a yes/no question that captures almost nothing useful. A good family history goes through each first-degree and second-degree relative individually, with specific questions about the type of diagnosis and the age of onset. Ideally it is reviewed before any tests are chosen, because it determines where to look hardest.

What this means for you

Do your homework before your next check-up: call your parents, siblings and any living grandparents. Ask which conditions they have been diagnosed with and at what age. Write it down and bring it to your doctor. This 20-minute phone call may be one of the most valuable things you do for your own health — because it tells your physician where to look hardest.

References

  1. Guttmacher AE, et al. Genomic medicine — a primer. N Engl J Med. 2002;347(19):1512-1520.
  2. Win AK, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(3):404-412.
  3. Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated. Eur Heart J. 2013;34(45):3478-3490.
  4. The InterAct Consortium. The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study. Diabetologia. 2013;56(1):60-69. doi:10.1007/s00125-012-2715-x
  5. Orlando LA, et al. At the intersection of precision medicine and population health: an implementation-effectiveness study of family health history based systematic risk assessment in primary care. BMC Health Serv Res. 2020;20:1015. doi:10.1186/s12913-020-05868-1
  6. Hanson H, et al. UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants. J Med Genet. 2021;58(2):135.
Prof. Dr. med. Markus Guba

Head of Liver Surgery and Transplantation at LMU University Hospital Munich. Edits this independent journal in a private capacity; views are his own. About →

This article is general information and not individual medical advice. Decisions about tests and treatment belong in a conversation with your own physician.